BioCentury
ARTICLE | Company News

Piqur, Eisai deal

February 22, 2016 8:00 AM UTC

Piqur will conduct a Phase I/IIb trial combining breast cancer drug Halaven eribulin mesylate from Eisai with the biotech’s PQR309 to treat triple-negative breast cancer (TNBC). PQR309, a phosphoin...